ZURICH/ LONDON (Oct 22): Swiss drugmaker Roche beat third-quarter sales expectations on Thursday, supported by steady demand for key medicines such as Ocrevus to buy time as it looks abroad to restock a pipeline facing looming patent expiries.

Group revenue rose 7% at constant exchange rates to 16.13 billion Swiss francs (US$19.61 billion), exceeding a company-compiled consensus forecast of 15.75 billion francs (US$19.15 billion).

But the quarter brought an early warning of competitive pressure — blockbuster Xolair missed market forecasts after the first cheaper copycat launched, generating sales of 848 million francs (US$1.03 billion) against expectations of 925 million francs (US$1.12 billion).

Shares fell 1.1% in morning trade.

With several older blockbuster drugs nearing patent expiry, Roche is banking on its biggest products to drive near-term growth while stepping up external dealmaking for next-generation treatments. The company has struck a deal worth over US$15 billion with China's Hansoh Pharma, it was reported Monday.

Taking aim at Europe's biotech ecosystem, CEO Thomas Schinecker said on Thursday that roughly 50% of the group's external licensing deals over the past four years were made in the US and the other 50% in China and Asia.

"This shows you a little bit the status where Europe is in terms of its innovation," Schinecker said.

Management also noted the drag from China's healthcare pricing reforms was easing despite double-digit declines there, with the diagnostics division — which grew 5% to 3.54 billion francs (US$4.30 billion) — set to return to "normal" mid- to high-single-digit growth next year.

Roche also benefitted from a stabilising dollar against the Swiss franc, easing prolonged exchange-rate drag in a North American market that accounts for nearly half of group revenue.

Top-selling therapies drove the pharmaceutical unit, led by multiple sclerosis shot Ocrevus, which rose 9% at constant currencies to 1.84 billion francs (US$2.24 billion).

Uploaded by Liza Shireen Koshy